Debate

Roles of hyaluronan in bone resorption

Charles W Prince*

Address: Webb Nutrition Sciences Building, Room 324, Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL USA

Email: Charles W Prince* - princecw@uab.edu

* Corresponding author

Abstract

**Background:** Hyaluronan, an unsulfated glycosaminoglycan, while being closely linked to osteoclast function several years ago, has received little attention lately. Given recent new knowledge of hyaluronan’s possible cell binding abilities, it is important to re-examine the role of this polysaccharide in bone homeostasis.

**Discussion:** Previously published data demonstrating a linkage between induction of hyaluronan synthesis and osteoclast-mediated bone resorption are reviewed. Suggestions are made involving the cell binding ability of hyaluronan and its potential to mediate osteoclast binding to bone surfaces and its potential to serve as a diffusion barrier and participate in the sealing zone required for osteoclast-mediated bone resorption.

**Summary:** This brief article summarizes previous studies linking HA to bone resorption and suggests roles for hyaluronan in the process of bone resorption.

Background

Hyaluronan (HA) is an unsulfated glycosaminoglycan consisting of a single repeating disaccharide unit (1,4-glucuronic acid-β-1,3-N-acetylglucosamine-β). HA is about 1–10% of cartilage glycosaminoglycans, but it is also widely distributed in other tissues, e.g. in the skin, the eye, and in most body liquids [1]. HA is an important component of connective tissue matrices where its functions include promoting matrix assembly and tissue hydration and viscosity of some fluids, and modulating cell-cell or cell-matrix interactions [1]. Recently, additional roles for HA in cell signaling have been elucidated which involve cellular hyaladherins such as CD44 and RHAMM (CD168) that have specific downstream signaling pathway(s) which can mediate HA-dependent functions [2].

Linkage of hyaluronan synthesis to bone resorption

Several studies [3-5] demonstrated that treatment in vivo with parathyroid gland extract (PTE) resulted in increased bone synthesis of hexosamine-containing compound(s). Based on such findings, Severson et al. [6] used organ cultures of neonatal mouse calvaria, treated with PTE and then labeled with 3H-glucosamine (glcN), to demonstrate that PTE caused a 4-fold increase in papain-resistant macromolecular material that was identified as hyaluronic acid, now called hyaluronan (HA). Luben and coworkers provided data that clearly linked parathyroid hormone (PTH)-induced synthesis of HA to bone resorption. Using organ cultures of bones pre-labeled in vivo with 45Ca++, they demonstrated that in vitro treatment with PTH followed by radiolabeling with 3H-glcN resulted in a 3–4-fold increase in HA synthesis [7]. This increase was detectable by 4 h and was maximal at 24 h. Changes in 45Ca++ release followed a parallel course but with a delayed onset
integrins, in particular the vitronectin receptor. Recent work has suggested that osteoclasts utilize HA, in particular CD44, a cell surface HA binding protein, to bind to one or more of the cell adhesion proteins, e.g. osteopontin or bone sialoprotein [13,14], though such binding may not occur at the sealing zone as previously supposed [15]. Since osteoclasts have recently been shown to possess cell surface proteins capable of binding to HA [16], in particular CD44, a cell surface HA binding protein [17] capable of supporting cell adhesion [18], HA may also regulate the osteoclast’s ability to bind to bone surfaces by acting alone or in conjunction with osteopontin, bone sialoprotein or other matrix proteins (likely synthesized by osteoclasts). Recent work by Spessoto et al., [19] supports this scenario and work by Suzuki et al., [20] confirms that osteoclasts from CD44/− mice are defective in bone resorption. In addition, given the large hydrodynamic volume of HA, it seems possible that it could participate in forming a diffusion barrier underneath the osteoclast, presumably at the sealing zone. One could speculate that any HA present in the ruffled membrane area would be degraded by lysosomal enzymes secreted from the osteoclasts.

It is instructive to note that while little is known about the bone enzymes responsible for degrading HA, i.e., hyaluronidase (EC 3.2.1.35), β-D-glucuronidase (EC 3.2.1.31), and N-acetyl-β-D-hexosaminidase (EC 3.2.1.30), genetic deficiencies of β-D-glucuronidase (Sly syndrome, [21]) or N-acetyl-β-D-hexosaminidase (Sandhoff Disease, [22]), result in numerous skeletal deformities, suggesting that these enzymes have important roles in normal bone homeostasis.

On the other hand, an additional role of HA may be in modulating osteoblast adhesion to osteoid or bone surfaces. In their model of hormonal regulation of bone resorption, Rodan and Martin [23] suggested that PTH induces osteoblasts, which form a contiguous layer on the bone surface, to change shape, thereby allowing osteoclasts access to the bone surface, a prerequisite for bone resorption. Given that osteoblasts exhibit vectorial secretion, i.e., directed toward the underlying bone surface, and that HA has a large molecular size and hydrodynamic volume, HA synthesized by osteoblasts may prove to be a molecular lever of sorts, capable of prying osteoblasts from the osteoid surface or from one another, disrupting the continuity of the lining layer of cells. Thereafter, in such a scenario, the HA could serve as an adhesion substrate for incoming osteoclasts and, possibly, act as a diffusion barrier at the sealing zone. In this regard the recent findings of Midura et al., are pertinent – they found that HA content of bone extracellular matrix was substantially increased by PTH treatment and that this was a direct response to the peptide hormone [24].

Another scenario is suggested by the recent work by Fujii et al., [25] who demonstrated that ligation of osteoblast CD44 with HA regulates adhesion molecule expression of osteoblasts and increases their binding to macrophage-like cells. These authors suggested that the interactions of CD44 and HA may play a role in osteoclastogenesis.

Summary
1. HA synthesis is tightly coupled to onset of bone resorption
2. HA's roles in cell adhesion and in limiting diffusion suggest mechanisms for its involvement in osteoclast-mediated bone resorption.
3. These mechanisms include cell binding, and/or acting as a molecular lever or diffusion barrier

4. Additional studies are needed to clarify the roles that HA has in bone metabolism in general and in bone resorption specifically.

Competing interests
None declared.

Author’s contributions
CWP was solely responsible for the content of this article.

References
1. Laurent TC, Laurent UB, Fraser JR: The structure and function of hyaluronan: An overview. Immunol Cell Biol 1996, 74:A1-7.
2. Fraser JR, Laurent TC, Laurent UB: Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 1997, 242:27-33.
3. Owen M, Shetlar MR: Uptake of [3H]glucosamine by osteoclasts. Nature 1968, 220:1335-1336.
4. Shetlar MR, Shurley H, Hern D: The effects of parathyroid extract upon incorporation of 1-14C-glucosamine into bone. Proc Soc Exp Biol Med 1972, 139:340-344.
5. Johnston CC, Smith DM, Severson AR: Bone resorption and matrix hexosamine labeling. Calcium, Parathyroid Hormone and the Calcitonins Edited by: Talmage RV, Munson PL. Amsterdam, Excerpta Medica Foundation; 1972:327-337.
6. Severson AR, Rothberg PF, Pratt RM, Goggins JF: Effect of parathryroid hormone on the incorporation of 3H-glucosamine into hyaluronic acid in bone organ culture. Endocrinology 1973, 92:1282-1285.
7. Luben RA, Goggins JF, Raiss LG: Stimulation by parathyroid hormone of bone hyaluronate synthesis in organ culture. Endocrinology 1974, 94:737-745.
8. Luben RA, Cohn DV: Effects of parathormone and calcitonin on citrate and hyaluronate metabolism in cultured bone. Endocrinology 1976, 98:413-419.
9. Wener J, Gorton SJ, Raiss LG: Escape from inhibition of resorption in cultures of feline bone treated with calcitonin and parathyroid hormone. Endocrinology 1972, 90:752-759.
10. Wong GL, Kokour BA: Differential sensitivity of osteoclasts and osteoblasts suggests that prostaglandin E1 effects on bone may be mediated primarily through the osteoclasts. Arch Biochem Biophys 1983, 224:29-35.
11. Wong GL: Paracrine interactions in bone-secreted products of osteoclasts permit osteoclasts to respond to parathyroid hormone. J Biol Chem 1984, 259:4019-4022.
12. Stern PH, Raiss LG: Organ culture of bone. Skeletal Research, An Experimental Approach 2nd edition. Edited by: Simmons DJ, Kunin AS. New York, Academic Press, Inc; 1979:44.
13. Reinholt FP, Hultenby K, Olberg A, Heinegard D: Osteopontin—n possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA 1989, 87:4473-4475.
14. Helfrich MH, Nesbitt SA, Dorey EL, Horton MA: Rat osteoclasts adhere to a wide range of RGD (Arg-Gly-Asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via a beta3 integrin. J Bone Miner Res 1992, 7:335-343.
15. Lakkakorpi PT, Horton MA, Helfrich MH, Karhukorpi E-K, Vaananen HK: Vitronectin receptor has a role in bone resorption but does not mediate tight sealing zone attachment of osteoclasts to the bone surface. J Cell Biol 1991, 111:1179-1186.
16. Athanasou NA, Quinn J: Immunophenotypic differences between osteoclasts and macrophage polykaryons: immunohistological distinction and implications for osteoclast ontogeny and function. J Clin Pathol 1990, 43:997-1003.
17. Aruffo A, Stamamekovic I, Melnick M, Underhill CB, Seed B: CD44 is the principal cell surface receptor for hyaluronate. Cell 1990, 61:1303-1313.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2474/5/12/prepub